--- title: "Veradermics (MANE) news: IPO and offering" url: "https://aibio.space/companies/veradermics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MANE IPO and offering news: Veradermics completes $294.8 million IPO with full overallotment exercise. Veradermics, Incorporated (NYSE: MANE), United States." --- MANE Veradermics, Incorporated NYSE · United States # Veradermics (MANE) news MANE IPO and offering news Financings · 2026-08-21 ## [Veradermics CEO, technical chief and two large holders sell shares in August](https://aibio.space/news/veradermics-ceo-technical-chief-two-large-holders-sell-shares-august/) Insiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales. ## Latest Veradermics news 1. 2026-08-11 Financings [Veradermics reports $819.9 million in cash and securities, sees funding into 2030](https://aibio.space/news/veradermics-reports-819-9-million-cash-securities-sees-funding-2030/) Veradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026. 2. 2026-05-01 Financings [Veradermics raises about $472 million in $100-a-share follow-on and warrant sale](https://aibio.space/news/veradermics-raises-about-472-million-100-share-follow-warrant-sale/) Veradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses. 3. 2026-02-05 Financings [Veradermics completes $294.8 million IPO with full overallotment exercise](https://aibio.space/news/veradermics-completes-294-8-million-ipo-full-overallotment-exercise/) Veradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares. ## Veradermics at a glance - **Ticker**: MANE - **Listing**: NYSE - **Country**: United States - **Cash, Jun 30, 2026**: $819.9 million ### Related companies - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY - [SCYNEXIS](https://aibio.space/companies/scynexis/) NASDAQ: SCYX - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) NASDAQ: EIKN - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Xenetic Biosciences](https://aibio.space/companies/xenetic-biosciences/) NASDAQ: XBIO - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) NASDAQ: SGMT - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH ### Also on NYSE - [QIAGEN](https://aibio.space/companies/qiagen-n-v/) QGEN - [Hercules Capital](https://aibio.space/companies/hercules-capital/) HTGC - [Pfizer](https://aibio.space/companies/pfizer-pfe/) PFE - [ZIMMER BIOMET HOLDINGS, INC.](https://aibio.space/companies/zimmer-biomet/) ZBH - [Eli Lilly](https://aibio.space/companies/eli-lilly/) LLY - [Ginkgo Bioworks Holdings](https://aibio.space/companies/ginkgo-bioworks/) DNA ## Veradermics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$62.1 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | [$23.3 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | | Net income (loss) | [-$70.0 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | [-$26.5 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | | Cash from operations | [-$71.6 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | [-$23.7 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | | Cash and equivalents | [$21.8 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/) | [$53.1 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | | Short-term investments | [$120.1 million](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/) | [$0](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $319.3 million, plus short-term investments of $500.6 million, $819.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Veradermics When did Veradermics go public? Our latest story on this, dated Feb 5, 2026: "Veradermics completes $294.8 million IPO with full overallotment exercise". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/veradermics-completes-294-8-million-ipo-full-overallotment-exercise/). Has Veradermics raised money recently? Our latest story on this, dated May 1, 2026: "Veradermics raises about $472 million in $100-a-share follow-on and warrant sale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/veradermics-raises-about-472-million-100-share-follow-warrant-sale/). What is the ticker symbol of Veradermics? Veradermics, Incorporated trades under the ticker MANE on NYSE. Where is Veradermics listed? Veradermics, Incorporated is listed on NYSE. What is the SEC CIK of Veradermics? The SEC Central Index Key (CIK) for Veradermics, Incorporated is 1827635. Its filings are on SEC EDGAR. How many shares does Veradermics have outstanding? 41,780,136 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Veradermics listed under? Our directory records Veradermics, Incorporated under United States. What does Veradermics do? Our directory classifies Veradermics, Incorporated as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Veradermics? The ISIN recorded for Veradermics, Incorporated is US9229671048. Does aibio.space cover Veradermics? aibio.space lists Veradermics, Incorporated among 2,820 public biotech companies and publishes its news here as stories appear. Where is Veradermics incorporated? SEC records list its state or country of incorporation as DE. Is Veradermics profitable? Veradermics, Incorporated reported a net loss of $70.0 million for the fiscal year ended Dec 31, 2025, and used $71.6 million of cash in operations, per its annual report to the SEC. How much does Veradermics spend on research and development? $62.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Veradermics have? $819.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Veradermics (MANE) stock news? Our latest story on Veradermics, dated Aug 21, 2026: "Veradermics CEO, technical chief and two large holders sell shares in August". Insiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales. [Source](https://aibio.space/news/veradermics-ceo-technical-chief-two-large-holders-sell-shares-august/). ## Investor discussion: Veradermics Members talk about Veradermics (MANE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Veradermics, newest first. Each line links the filing it comes from. 1. 2026-08-11 Financing The quarterly report said the May follow-on offering of 4,420,358 shares, including 576,568 shares from the full underwriters' option, raised approximately $442.0 million gross. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/mane-20260630.htm) 2. 2026-05-15 Financing The private-placement Form D reported $29,999,997 sold. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000020/xslFormDX01/primary_doc.xml) 3. 2026-05-01 Financing Veradermics closed a public offering of 3,843,790 common shares at $100.00 each and a concurrent private placement of pre-funded warrants for approximately $30.0 million gross. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/mane-20260501.htm) 4. 2026-04-29 Financing The issuer and investors entered the private-placement purchase agreement. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/mane-20260501.htm) 5. 2026-04-27 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000162828026027631/follow-on2026pfw.htm) 6. 2026-03-30 Financing The annual report disclosed the completed 2025 Series C aggregate of $151 million. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/mane-20251231.htm) 7. 2026-03-30 Financing The annual report disclosed Series B follow-on closings in January and February 2025. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/mane-20251231.htm) 8. 2026-02-05 Financing The quarterly report dates the completed IPO to this day, with gross proceeds of approximately $294.8 million. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/mane-20260630.htm) 9. 2026-02-04 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000162828026005505/veradermicsinc424b4.htm) 10. 2026-01-27 Reverse split The issuer effected a one-for-10.067 reverse split before the IPO. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/mane-20260630.htm) 11. 2026-01-09 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm) 12. 2025-10-28 Financing The private-offering notice reported $134,999,978 sold and $15 million remaining. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000123191925000361/xslFormDX01/primary_doc.xml) 13. 2025-10-14 Financing The Series C private-offering notice identifies this as its first sale date. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000123191925000361/xslFormDX01/primary_doc.xml) 14. 2024-12-10 Financing The private-offering notice reported $66,567,075 sold against a $75 million total. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763524000001/xslFormDX01/primary_doc.xml) 15. 2024-11-25 Financing The issuer entered a Series B purchase agreement and converted earlier notes into preferred stock. [Source](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000013/mane-20251231.htm) ## Investor questions about Veradermics ### How much liquidity did the latest quarter report? At 2026-06-30, cash and equivalents were $319.333 million and current-asset marketable securities were $500.561 million. These are dated balances, not a current bank confirmation. Source ### What funding horizon did management state? The quarterly report forecasts funding into 2030 under the current operating plan. It says assumptions could prove wrong and resources could run out earlier. Source ### Does the latest filing conclude unresolved substantial doubt? No unresolved substantial-doubt conclusion was found in the opened annual or quarterly report. Both give an affirmative assessment of ability to meet obligations for at least twelve months. Source ### How much cash did operations use in the latest quarter? Derived second-quarter use was $14.490 million: half-year operating use of $35.658 million less first-quarter use of $21.168 million. This calculation is not a separately reported quarter-only cash-flow line. Source ### Did MANE implement a reverse split? A one-for-10.067 reverse split became effective on 2026-01-27 before the IPO. The opened source does not describe it as an exchange deficiency cure. Source ### Has an open exchange deficiency been verified? No open deficiency or delisting proceeding was verified in the opened history. The latest quarterly cover identifies the New York Stock Exchange. Source ### What was the public-offering price in May? The historical subscription price was $100.00 per common share. This is a financing term, not a current market quotation. Source ### Does a pre-funded warrant exercise bring in the full subscription amount again? No. Almost all of the purchase price was paid at issuance, while the exercise price was $0.00001 per share. The later 13D reports cash exercises of the warrants. Source ### Does the August resale prospectus establish completed sales? No. It permits holder dispositions but says the issuer cannot predict whether or when holders may sell. It does not establish receipt of the selling holders proceeds by the issuer. Source ### Was a specific shareholder lawsuit verified? No specific class action or derivative action was verified. The quarterly legal disclosure is management assessment of materiality, not a universal no-litigation certification. Source ### Who audits the company? Deloitte & Touche LLP signed the latest annual audit and states service since 2023. Source ### Can the large-holder percentages be added together? They are measured at different dates and may use different denominators. Source ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:MANE on TradingView](https://www.tradingview.com/symbols/NYSE-MANE/). ## SEC filings and registration - **SEC name**: Veradermics, Inc - **CIK**: 1827635 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MANE (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 470 JAMES STREET, NEW HAVEN, CT, 06513 - **Phone**: 228.372.3376 - **Shares outstanding**: 41,780,136 as of 2026-08-06 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/mane-20261019.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/mane-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/mane-20260811.htm) filed 2026-08-11 - [S-1](https://www.sec.gov/Archives/edgar/data/1827635/000162828026054921/veradermics-sx1august2026.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/mane-20260715.htm) filed 2026-07-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000019/mane-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/mane-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/mane-20260501.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001827635), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Veradermics, Incorporated is a public biotech or pharmaceutical company listed on NYSE under the ticker MANE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Veradermics, Incorporated - **Ticker**: MANE - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US9229671048 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-MANE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/veradermics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Veradermics (MANE) news: IPO and offering", 2026-10-31, https://aibio.space/companies/veradermics/